The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes
- 6 May 2010
- journal article
- review article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 6 (3), 257-264
- https://doi.org/10.1016/j.jalz.2010.03.002
Abstract
Background: The Alzheimer's Disease Neuroimaging Initiative Phase 1 (ADNI-1) is a multisite prospective study designed to examine potential cerebrospinal fluid and imaging markers of Alzheimer's disease (AD) and their relationship to cognitive change. The objective of this study was to provide a global summary of the overall results and patterns of change observed in candidate markers and clinical measures over the first 2 years of follow-up. Methods: Change was summarized for 210 normal controls, 357 mild cognitive impairment, and 162 AD subjects, with baseline and at least one cognitive follow-up assessment. Repeated measures and survival models were used to assess baseline biomarker levels as predictors. Potential for improving clinical trials was assessed by comparison of precision of markers for capturing change in hypothetical trial designs. Results: The first 12 months of complete data on ADNI participants demonstrated the potential for substantial advances in characterizing trajectories of change in a range of biomarkers and clinical outcomes, examining their relationship and timing, and assessing the potential for improvements in clinical trial design. Reduced metabolism and greater brain atrophy in the mild cognitive impairment at baseline are associated with more rapid cognitive decline and a higher rate of conversion to AD. Use of biomarkers as study entry criteria or as outcomes could reduce the number of participants required for clinical trials. Conclusions: Analyses and comparisons of ADNI data strongly support the hypothesis that measurable change occurs in cerebrospinal fluid, positron emission tomography, and magnetic resonance imaging well in advance of the actual diagnosis of AD.Funding Information
- National Institutes of Health (U01 AG024904)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- National Institutes of Health (P30 AG010129, K01 AG030514)
This publication has 27 references indexed in Scilit:
- Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCINeurobiology of Aging, 2011
- Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging InitiativeNeuroImage, 2010
- Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjectsNeuroImage, 2009
- Relationships between biomarkers in aging and dementiaNeurology, 2009
- Conversion of amyloid positive and negative MCI to AD over 3 yearsNeurology, 2009
- Imaging and Biomarkers in Early Alzheimer's Disease and Mild Cognitive ImpairmentClinical Pharmacology & Therapeutics, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's diseaseBrain, 2009
- MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkersBrain, 2008
- PENN Biomarker Core of the Alzheimer’s Disease Neuroimaging InitiativeNeurosignals, 2007